Indication
Familial hypokalemic periodic paralysis
Familial hypokalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy primarily affecting skeletal muscle, typically manifesting during late childhood or adolescence. Read more about Familial hypokalemic periodic paralysis
5 drugs 5 manufacturers
Drugs that treat it
Common Familial hypokalemic periodic paralysis therapies.
KEVEYIS (dichlorphenamide)
ORMALVI (dichlorphenamide)
DICHLORPHENAMIDE
DICHLORPHENAMIDE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonFamilial hypokalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy primarily affecting skeletal muscle, typically manifesting during late childhood or adolescence.
It is predominantly caused by pathogenic variants in genes encoding voltage-gated calcium or sodium channels, such as CACNA1S and SCN4A, which disrupt sarcolemmal membrane excitability.
Pathophysiologically, aberrant ion conductance leads to paradoxical muscle cell depolarization and an abnormal intracellular shift of potassium.
Clinically, the disorder is characterized by reversible, episodic attacks of flaccid muscle weakness or paralysis—most notably involving the proximal limbs—concomitant with serum hypokalemia, frequently provoked by rest following strenuous exercise, carbohydrate-rich meals, or physiological stress.
- nih.gov
Familial hypokalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy primarily affecting skeletal muscle, typically manifesting during late childhood or adolescence It is predominantly caused by pathogenic variants in genes encoding voltage-gated calcium or sodium channels, such as CACNA1S and SCN4A, which disrupt sarcolemmal membrane excitability Clinically, the disorder is characterized by reversible, episodic attacks of flaccid muscle weakness or paralysis—most no...
- medlineplus.gov
Familial hypokalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy primarily affecting skeletal muscle, typically manifesting during late childhood or adolescence
- nih.gov
Familial hypokalemic periodic paralysis is a rare, autosomal dominant neuromuscular channelopathy primarily affecting skeletal muscle, typically manifesting during late childhood or adolescence It is predominantly caused by pathogenic variants in genes encoding voltage-gated calcium or sodium channels, such as CACNA1S and SCN4A, which disrupt sarcolemmal membrane excitability
- medlineplus.gov
Pathophysiologically, aberrant ion conductance leads to paradoxical muscle cell depolarization and an abnormal intracellular shift of potassium Clinically, the disorder is characterized by reversible, episodic attacks of flaccid muscle weakness or paralysis—most notably involving the proximal limbs—concomitant with serum hypokalemia, frequently provoked by rest following strenuous exercise, carbohydrate-rich meals, or physiological stress
- rarediseases.org
Clinically, the disorder is characterized by reversible, episodic attacks of flaccid muscle weakness or paralysis—most notably involving the proximal limbs—concomitant with serum hypokalemia, frequently provoked by rest following strenuous exercise, carbohydrate-rich meals, or physiological stress
Personalize your experience
Follow Familial hypokalemic periodic paralysis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.